Topiramate‐induced metabolic acidosis: report of two cases

Two children who presented with symptomatic metabolic acidosis after being put on topiramate (TPM) are reported. The first patient was an 11‐year‐old male with refractory complex partial epilepsy who was put on TPM for 13 months. He developed hyperventilation 1 week after increasing the dose to 300mg/day. Arterial blood gas revealed hyperchloraemic metabolic acidosis with partial respiratory compensation: pH 7.36, PCO2 27.2 mmHg, bicarbonate 14.9 mEq/L, base excess ‐8.9 mmol/L. Hyperventilation and acidosis resolved after administration of sodium bicarbonate and reduction of the dose of TPM. The second patient was a female who developed increasing irritability at age 16 months and 21 months, each time associated with introduction of TPM and resolved promptly upon withdrawal of the drug. Venous blood gas taken during the second episode revealed pH 7.34, PCO2 37.4 mmHg, bicarbonate 20.4 mEq/L, base excess ‐4.2 mmol/L. The predominant mechanism of TPM‐induced hyperventilation involves inhibition of carbonic anhydrase at the proximal renal tubule, resulting in impaired proximal bicarbonate reabsorption. The occurrence of hyperpnoea or mental status change in any patient who is on TPM should prompt an urgent blood gas sampling, with correction of the acid‐base disturbances accordingly.

[1]  G. Solomon Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. , 2000, Neurology.

[2]  T. Glauser,et al.  An improved gas chromatography assay for topiramate monitoring in pediatric patients. , 2000, Therapeutic drug monitoring.

[3]  N. Patel,et al.  Central hyperventilation related to administration of topiramate. , 2000, Pediatric neurology.

[4]  E. Perucca,et al.  Is There a Role for Therapeutic Drug Monitoring of New Anticonvulsants? , 2000, Clinical pharmacokinetics.

[5]  R. Shank,et al.  Topiramate as an Inhibitor of Carbonic Anhydrase Isoenzymes , 2000, Epilepsia.

[6]  H. Farrar,et al.  Acute Mental Status Changes and Hyperchloremic Metabolic Acidosis with Long‐Term Topiramate Therapy , 2000, Pharmacotherapy.

[7]  T. Glauser,et al.  Topiramate in Lennox–Gastaut Syndrome: Open‐Label Treatment of Patients Completing a Randomized Controlled Trial , 2000, Epilepsia.

[8]  R. Shank,et al.  An Overview of the Preclinical Aspects of Topiramate: Pharmacology, Pharmacokinetics, and Mechanism of Action , 2000, Epilepsia.

[9]  E. Wyllie,et al.  Effectiveness, Tolerability, and Safety of Topiramate in Children with Partial‐Onset Seizures , 2000, Epilepsia.

[10]  T. Glauser,et al.  Long‐Term Response to Topiramate in Patients with West Syndrome , 2000, Epilepsia.

[11]  J. W. A. S. Sander,et al.  Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. , 2000, Neurology.

[12]  A. Wilner,et al.  Topiramate and Metabolic Acidosis , 1999, Epilepsia.

[13]  W. Rosenfeld,et al.  Comparison of the Steady‐State Pharmacokinetics of Topiramate and Valproate in Patients with Epilepsy During Monotherapy and Concomitant Therapy , 1997, Epilepsia.